Can a simple blood test spot who will die from H1N1?
NCT ID NCT03641690
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study measured levels of mannose-binding lectin (MBL), a protein involved in immune response, in 97 ICU patients with severe H1N1-related acute respiratory distress syndrome (ARDS). Researchers wanted to see if higher or lower MBL levels were linked to a higher risk of death. The goal was to find a simple blood test that could help doctors identify the sickest patients sooner.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors identify high-risk H1N1 patients earlier, potentially guiding more aggressive treatment.
- What could go wrong
- This is an observational study, not a treatment trial. It only looks for a link between a blood marker and outcomes, so it cannot prove cause or lead directly to a new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for H1N1 INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens-Picardie
Amiens, 80054, France